651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III

Hyperuricemia modifies multiple myeloma pathobiology and modulates conventional novel and immuno oncology drug sensitivity

Functional genomic screens identify positive and negative regulators of venetoclax resistance

Subclonal genomic heterogeneity shapes immune crosstalk and clinical outcomes in multiple myeloma

Pomalidomide promotes activation induced cell death of pre activated memory BCMA CAR T cells in a model of high but not low tumor burden multiple myeloma

Fingolimod in combination with bortezomib demonstrates synergistic tumor inhibition and bone anabolic effects in myeloma bone disease

Tryptophan metabolism plays a significant role in multiple myeloma survival

CAR T cells manufactured after multiple myeloma triplet or quadruplet induction therapy have reduced functionality and an altered composition

Transitioning from FISH to NGS for immunoglobulin translocation detection in multiple myeloma

P300 CBP acetyltransferase inhibition and degradation disrupt oncogenic transcriptional programs and reveal epigenetic vulnerabilities in multiple myeloma

A multimodal machine learning framework to predict treatment duration in multiple myeloma patients

PRL 3 enhances multiple myeloma cell survival in acidic microenvironments via metabolic adaptation and pH regulation

MAPK pathway driven metabolic inflammatory axis in AL amyloidosis

NAMPT in macrophages promotes multiple myeloma drug resistance through mitochondrial metabolic reprogramming and modulates immunosuppression via the SIRT1 STAT3 SPP1 axis

Methionine promotes glycolysis and tumor progression in multiple myeloma by enhancing POU2AF1 expression via m⁶A modification

BIRC5 inhibition as a novel approach to target RAS mutant and drug resistant multiple myeloma

Bone marrow spatial architecture predicts response duration in smoldering multiple myeloma patients receiving checkpoint inhibitor therapy

The m5C binding protein YB 1 modulates proteasome inhibitors resistance in multiple myeloma via epigenetic modification

EZH2 inhibition synergizes with aiolos ikaros degradation via coordinated chromatin remodeling and FoxO activation in multiple myeloma

Single cell profiling reveals teclistamab induced reshaping of nasopharyngeal immunity in multiple myeloma

Pharmacodynamic activity and clinical benefits of mezigdomide in high risk biomarker subgroups from the CC 92480 MM 001 study

Chromothripsis drives high risk multiple myeloma by copy number abnormalities and rewiring the epigenome to activate oncogenic programs